Mammalian Cell Culture Production Media MAM-PF ®

Mammalian Cell Culture Production Media MAM-PF
Life Science Solutions Index

Enquiries

If you have any questions about products featured on this site, or on products that you cannot find on this site, please contact us and we will be happy to assist you in any way that we can. We have a team of technical sales specialists who are waiting to hear from you!

Contact Us

Home > Life Science Solutions > Cell Culture Media > Mammalian Cell Culture Production Media MAM-PF ®

Print this page

Back

Mammalian Cell Culture Production Media MAM-PF ®

BioConcept Ltd has been able to manufacture and supply a new form of Mammalian Cell Culture Media thanks to the breakthrough in recombinant protein production. MAM-PF® known as Mammalian Artificial Media is a line of media tailor made to satisfy the needs of large-scale therapeutics and biosimilars producers**. The Mammalian Cell Culture Media is Animal Component Free and is produced in accordance with EMA/410/01.

MAM-PF® Cell Culture Media is also protein-free, protein hydrolysates free and chemically defined. It can be used for high-density cell culture of a variety of cell lines, including CHO (Chinese Hamster Ovary) cells, and BHK (Baby Hamster Kidney) cells, as well as high-level recombinant proteins expression. BioConcept holds a certificate for each component used in the MAM-PF® media series, ensuring a clean and high-quality finished product.

Benefits of MAM-PF® Series:

  • Protein and protein hydrolysates free

  • Chemically Defined

  • Best glycosylation pattern can be observed

  • Easy to adapt from current medium to MAM-PF Medium

  • High-cell density combined with high product yield

  • Antibody product of up to 5.5 g/L

  • EPO of up to 2.5 g/L

  • Cell density of up to 3.7 x 10 to the power 7 cells/ml    

  • Liquid batch capacity ranging from 5-10,000 litres

  • Powder batch capacity from 1 – 800 kg

Selection of pre-developed biosimilars produced with MAM-PF® media series:


API

(Indication)

Available

(EUGENEX Biotechnologies)

Brand Name

(Orginator)

EPO, Epoetin alpha (Anemia)

Cell-Line & USP & DSP

Epogen (Amgen)

Eprex (Johnson)

DPO, Darbepoetin alpha (Anemia)

Cell-Line & USP & DSP

Aranesp (Amgen)

INFb, Interferon beta 1a

(MS)

Cell-Line & USP & DSP

Avonex (Biogen)

Rebif (Serono)

FSH, follicle stimulating hormone (Infertility); also hCG & LH

Cell-Line & USP & DSP

Gonal-F (Serono)

Puregon (Organon)

Etanercept, TNFa receptor IgG (chronical arthritis, psoriasis)

Cell Line

USP & DSP

Enbrel (Amgen, Pfizer, Takeda)

Adalimumab, TNFa Mab (rheumatoid arthritis, Crohn’s)

Cell Line

USP & DSP

Humira (Abbott)

Rituximab, CD20 Mab (rheumatoid arthritis, lymphoma)

Cell Line

USP & DSP

Rituxan (Roche)

Trastuzumab, HER2 Mab (mammacarcinom)

Cell Line

USP & DSP

Herceptin (Roche)

Bevacizumab, VEGF Mab (colorectal cancer)

Cell Line

USP & DSP

Avastin (Roche)

Cetuximab, EGF receptor Mab (colorectal cancer)

Cell Line

USP

Erbitux (BMS,Imclone)

Omalizumab, IgE Mab (persistent allergic asthma)

Cell Line

USP

Xolair (Genentech/Novartis)

Denosumab, RANKL IgG (osteoporosis, colorectal cancer)

Cell Line

USP

Prolia (Amgen)

Eculizumab, Complement C5 Mab (hemoglobinuria (PNH))

Cell Line

USP

Soliris (Alexion)

Ipilimumab, CTLA-4 IgG1 (metastatic melanoma)

Cell Line

USP

Yervoy (BMS)

Tocilizumab, IL-6R IgG1 (Castelman, rheumatoid arthritis)

Cell Line

Actemra (Roche, Chugai)

Abatacept, CTLA-4-IgG1 fusion (rheumatoid arthritis)

Cell Line

Orencia (BMS)

Pertuzumab, Her2 dimer inhibitor (metastatic breast cancer)

Cell Line

USP

Omnitarg (Roche)

Panitumumab, EGF-R Mab (colorectal cancer)

Cell Line

Vectibix (Genentech/Novartis)

Ofatumumab, CD20 IgG1 2nd Gen. (leukemia and others)

Cell Line

Arzerra (Genmab/GSK)